Status:
COMPLETED
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Multiple Indications Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide d...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol
- Receiving dasatinib at the time of signature of informed consent
- Males and Females, ages 18 and older
Exclusion
- All patients previously discontinued from a dasatinib study for any reason
- Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
- History of allergy to dasatinib
Key Trial Info
Start Date :
July 31 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2022
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT02297139
Start Date
July 31 2015
End Date
May 15 2022
Last Update
May 6 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Besançon, France, 25000
2
Local Institution - 0006
Krakow, Lesser Poland Voivodeship, Poland, 30-727
3
Local Institution
Chorzów, Poland, 41-500
4
Local Institution
Lodz, Poland, 93-510